A thread 10+ years in the making.
This one starts in 2009 when I was a postdoc in @skathire lab @MassGeneralNews/@broadinstitute studying ❤ risk factors like cholesterol & triglycerides.
(thread)
We scoured the literature and found that Dr. Gustav Schonfeld @WUSTLendo—an Auschwitz survivor, an immigrant to the US, a foremost expert on lipid metabolism—had identified 4 *healthy* siblings with a “double whammy”:
⬇️⬇️LDL & ⬇️⬇️triglycerides (TG)
nytimes.com/2017/05/24/hea…
Schonfeld hadn’t been able to pinpoint the causal gene with linkage analysis.
@skathire & I realized that a new technology unveiled in 2009—exome sequencing—might find the gene.
Schonfeld had DNA samples sent to us, and we applied exome sequencing to 2 of the 4 siblings.
With exome sequencing so new, 2 students in the lab—@jpirruccello & @DoGenetics—set up a pipeline from scratch.
On a wintry Saturday afternoon, the pipeline finally spit out the thrilling answer:
Each sibling had 2 nonsense mutations in ANGPTL3—natural gene “knockouts”!
ANGPTL3 was known to be linked to TG in mice, but not LDL.
That same year, GWAS of 100,000 people by @skathire, me, & many colleagues ➡️ common variants near ANGPTL3 linked to TG & LDL.
Thus:
⬇️PCSK9 = safe ⬇️LDL
⬇ANGPTL3 = safe ⬇️LDL & ⬇️TG
= candidate drug targets.
While at @MassGeneralNews, I met @JKeithJoung—a foremost expert on gene editing—and learned from him how to make and use zinc-finger nucleases (ZFNs) to edit cells.
As I was starting my own lab @HSCRB, I used ZFNs and then TALENs to edit stem cells for ❤️ disease modeling.
Subsequent work has shown PCSK9 editing persists for months to years in animal models—and might be permanent in human patients.
A one-and-done gene-editing therapy would be a new approach to reducing the 18 million deaths/year from ❤ disease.
sciencedaily.com/releases/2014/…
Xiao Wang in my lab used @Yecuris liver-humanized mice—the mouse’s own liver replaced with transplanted human liver cells—to show that Cas9 edits human PCSK9 in human liver cells in vivo efficiently.
Conclusion: if we could get Cas9 into the human liver, it would ⬇️ PCSK9.
Around this time (2016-17), @skathire & I teamed up again, showing people with an inactivating mutation in ANGPTL3 to be protected from ❤️ disease.
Independently shown by @Regeneron Genetics Center.
⬇️PCSK9 = safe ⬇️LDL & ⬇️❤️risk
⬇ANGPTL3 = safe ⬇️LDL & ⬇️TG & ⬇️❤️risk
The next big innovation in gene editing was the development of cytosine and adenine base editors by the lab of @davidrliu, reported in 2016 & 2017.
These base editors allow for specific C➡️T and A➡️G changes in the genome—more precise, more efficient, and safer than Cas9.
Alex Chadwick in my lab @PennMedicine used base editing in mouse liver to efficiently introduce nonsense mutations into PCSK9 or ANGPTL3.
With ⬇️ANGPTL3 in mice with high cholesterol, she observed:
>50%⬇️triglycerides
>50%⬇️LDL
A double whammy!
pubmed.ncbi.nlm.nih.gov/29483174/
PCSK9 antibodies were shown to reduce ❤️ disease but have to be injected every few weeks.
It was now clear that gene/base editing of PCSK9 or ANGPTL3 was also a viable approach to reduce ❤️ disease—1-shot therapies with possibly lifelong protection.
nature.com/articles/d4158…
The challenge now is to translate the gene editing to live human patients.
In 2018, @skathire, @JKeithJoung, & I were the scientific co-founders of @VerveTx, for which I serve as senior scientific advisor and where I’ve been on sabbatical this year.
inquirer.com/health/crispr-…
Today @VerveTx announced new data from non-human primates in which LNP-delivered adenine base editor ⬇️ PCSK9 or ANGPTL3 in the liver.
PCSK9:
67% editing
89%⬇️PCSK9 in blood
59%⬇LDL
ANGPTL3:
60% editing
95%⬇ANGPTL3 in blood
64%⬇TG
19%⬇LDL
businesswire.com/news/home/2020…
If these results can be reproduced in human patients, they’d rival or surpass the effects of all existing drugs that lower LDL or TG...
...but with a single treatment, rather than pills every day or injections every few weeks/months.
statnews.com/2020/06/27/cri… from @sxbegle
This is an important step—in a long series of steps—to translate genetic discoveries into therapies to fight the preeminent health threat of the 21st century.
It’s been an enthralling 10 years—let’s see what the next 10 years bring!
nytimes.com/2020/06/27/hea… from @ginakolata
Here are the non-human primate data presented by @skathire on behalf of @VerveTx in his keynote talk at #ISSCR2020.